Egetis Therapeutics AB Stock
Stocks
EGTX
SE0003815604
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Cboe Europe
04:01:03 2026-10-08 EDT
|
5-day change | 1st Jan Change | ||
| 9.605 SEK | +0.68% |
|
+9.03% | +80.90% |
| 10-02 | Four stocks have so far today hit new 52-week highs on the Stockholm Stock Exchange | FW |
| 10-01 | Feoh Investments increases stake in Egetis Therapeutics | FW |
| Market Cap | 4.44B 443M 396M 369M 335M 631M 42.83B 636M 1.73B 21.78B 1.66B 1.63B 70.03B | P/E 2026 * |
20.7x | P/E 2027 * | -43.6x |
|---|---|---|---|---|---|
| Enterprise Value | 3.44B 343M 307M 286M 260M 490M 33.23B 493M 1.34B 16.9B 1.29B 1.26B 54.32B | EV / Sales 2026 * |
6.4x | EV / Sales 2027 * | 7.17x |
| Free-Float |
37.69% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| EGTX | Delayed | |
CBOE
| Real-time | ||
|
London S.E.
| 0ABW | Delayed | |
|
OTC Markets
| PDPHF | Delayed | |
|
Börse Stuttgart
| P0F | Delayed | |
|
Deutsche Boerse AG
| P0F | Delayed | |
|
CBOE
| 0ABW | Real-time | |
|
Boerse Muenchen
| P0F | Real-time |
Last Transcript: Egetis Therapeutics AB
| 1 day | +0.84% | ||
| 1 week | +8.69% | ||
| Current month | +8.69% | ||
| 1 month | +25.88% | ||
| 3 months | +63.22% | ||
| 6 months | +69.54% | ||
| Current year | +80.34% |
| 1 week | 8.81 |  | 9.68 |
| 1 month | 7.36 | | 9.68 |
| Current year | 4.23 | | 9.68 |
| 1 year | 3.62 | | 9.68 |
| 3 years | 3.02 | | 9.68 |
| 5 years | 3 | | 9.68 |
| 10 years | 3 | | 48 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 2017-06-15 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 47 | 2017-12-30 |
Tiago Nune
CTO | Chief Tech/Sci/R&D Officer | - | 2026-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 2016-12-31 | |
Mats Blom
CHM | Chairman | 61 | 2024-05-05 |
Behshad Sheldon
BRD | Director/Board Member | 63 | 2022-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/2/26 | Sell | Executive/Senior Manager | -594 | 0.0001% | ||
| 8/31/26 | Exercice | Chief Financial Officer | 1,099 | 0.0002% | ||
| 8/31/26 | Buy | Chief Operating Officer | 1,099 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.84% | +8.69% | +86.99% | +145.35% | 443M | |
| +4.16% | +4.16% | +49.37% | +94.17% | 74.68B | |
| -16.79% | -17.09% | +1.54% | +49.42% | 58.7B | |
| -1.61% | +1.32% | +4.26% | +32.40% | 48.36B | |
| +0.50% | -2.14% | +331.33% | +702.20% | 43.05B | |
| -0.72% | -3.99% | +28.50% | +29.94% | 42.48B | |
| +0.34% | -0.52% | +6.56% | +109.35% | 41.39B | |
| -0.11% | +1.96% | +9.19% | +52.66% | 31.29B | |
| -0.50% | -3.10% | -10.19% | -14.35% | 23.93B | |
| -3.32% | -10.86% | -37.32% | +316.28% | 22.22B | |
| Average | -1.72% | -1.20% | +47.02% | +151.74% | 38.65B | |
| Weighted average by Cap. | -2.17% | -1.55% | +49.11% | +144.68% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 538M 53.67M 47.95M 44.74M 40.64M 76.54M 5.19B 77.11M 210M 2.64B 201M 197M 8.49B | 510M 50.96M 45.53M 42.48M 38.59M 72.67M 4.93B 73.21M 199M 2.51B 191M 187M 8.06B |
| Net income | 316M 31.54M 28.18M 26.3M 23.88M 44.98M 3.05B 45.32M 123M 1.55B 118M 116M 4.99B | -28.62M -2.86M -2.55M -2.38M -2.16M -4.07M -276M -4.1M -11.18M -141M -10.73M -10.49M -452M |
| Net Debt | -995M -99.3M -88.73M -82.78M -75.19M -142M -9.61B -143M -389M -4.89B -373M -365M -15.71B | -774M -77.22M -69M -64.37M -58.47M -110M -7.47B -111M -302M -3.8B -290M -284M -12.21B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-08 | SEK 9.660 | +1.26% | 410,704 |
| 26-10-07 | SEK 9.540 | -0.21% | 4,158,483 |
| 26-10-06 | SEK 9.560 | +5.52% | 4,008,629 |
| 26-10-05 | SEK 9.060 | -1.31% | 3,755,433 |
| 26-10-02 | SEK 9.180 | -2.75% | 6,060,584 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- EGTX Stock
Select your edition
All financial news and data tailored to specific country editions
